Asia Pacific Insulin Drug Market

Gan & Lee Pharmaceuticals lifted its 2025 revenue 33.1% to CNY 4.05 billion and its net profit 86.1%, crediting China’s volume-based procurement of insulin and coverage of 48,000 medical institutions, Tencent News reported from its annual results on 22 April 2026; Novo Nordisk’s insulin sales in Region China rose 5% to DKK 9,902 million while its volume share slipped to 41.0%, its 2025 financial report shows. Asia Pacific insulin is becoming a volume business won by local makers. The Asia Pacific insulin drug market covers human and analogue insulins, including once-weekly basal insulin and basal combinations, sold for use in Asia Pacific, valued at manufacturer net prices. Douglas Insights sizes it at USD 5.89 billion in 2025, from 19.8 million insulin patient-years at an average net USD 298 each, and at USD 8.62 billion in 2035, a revenue CAGR (compound annual growth rate) of 3.88%. It is the Asia Pacific row of our global Insulin Drug Market report, sits in our pharmaceuticals coverage, and every figure follows the Douglas Insights research methodology.

Which insulin type leads: basal analogues, premix pens or low-cost human insulin?

Long-acting basal analogues lead the Asia Pacific insulin drug market with 38.0% of 2025 value, USD 2.24 billion, and grow fastest, 5.10% a year to USD 3.68 billion, as China’s procurement makes glargine affordable.

Long-acting analogues, USD 2.24 billion, lead because basal glargine, degludec and detemir are now the standard first insulin in China, Japan, Korea and Australia. Gan & Lee’s Basalin, Sanofi’s Lantus and Toujeo and Novo Nordisk’s Tresiba and Levemir compete here, and the class grows 5.10% a year as tendered glargine reaches county hospitals and as Novo Nordisk’s Kyinsu, a weekly combination of icodec and semaglutide approved in China in March 2026, launches.

Premix insulins, USD 1.30 billion, hold 22.0% of value, about twice their weight in Europe, because Chinese and Indian doctors have long started type 2 patients on twice-daily premix pens such as NovoMix 30 and Humalog Mix25; they grow 2.40% a year as basal-first regimens spread. Rapid-acting analogues, USD 1.44 billion, grow 3.70% on mealtime aspart and lispro copies from Gan & Lee and Tonghua Dongbao. Human insulin, USD 913 million, still grows 2.60% a year because most first-time insulin users in India, Pakistan, Bangladesh and Indonesia start on low-cost vials. Class values for 2035 sum to USD 8.58 billion, 0.44% below the headline.

By diabetes type, Douglas Insights estimates that type 2 diabetes carries about 85% of 2025 value and type 1 diabetes about 15%, since the International Diabetes Federation counts only about 2.0 million people with type 1 diabetes across its Western Pacific and South-East Asia regions. By delivery format, prefilled pens carry about 55% of value, cartridges for reusable pens about 30% and vials about 15%; China’s reusable pens explain the high cartridge share. By channel, hospital pharmacies dispense about 65% of value, because Chinese insulin is mostly bought through public hospitals, and retail pharmacies about 35%.

What drives 4.40% a year more insulin patients, from China’s county hospitals to India’s towns?

Undertreated diabetes drives the Asia Pacific insulin drug market: patient-years rise 4.40% a year, from 19.8 million in 2025 to 30.5 million in 2035, as access widens faster than net price per patient falls.

The International Diabetes Federation counts about 215 million adults with diabetes in its Western Pacific region in 2024, half of them undiagnosed, and about 107 million in its South-East Asia region, 42.7% undiagnosed, rising to 254 million and 185 million by 2050, according to its Western Pacific and South-East Asia data. Only about one adult in sixteen with diabetes in the region uses insulin, Douglas Insights estimates, so access, not prevalence alone, sets volume. Four drivers add 5.30 gross points.

Affordable tendered insulin in China: 2.00 points

Procurement adds 2.00 points. China’s second insulin bulk-buying round drew demand for more than 240 million injections from more than 35,000 medical institutions, Yicai reported, and Gan & Lee said its first-year contracted volume in that round rose 32.6% over the first. Cheaper pens let county hospitals start patients who used to stay on tablets.

Diagnosis in India and Southeast Asia: 1.80 points

Diagnosis adds 1.80 points. India, Indonesia, Vietnam and the Philippines find more of their 45.6 million undiagnosed South-East Asia adults each year through screening drives, and human insulin vials are the first injectable they reach.

Earlier basal starts in type 2 diabetes: 1.00 point

Earlier basal insulin adds 1.00 point, as guidelines in China, Korea and Japan push doctors to start basal insulin when oral drugs fail, rather than years later.

Type 1 technology: 0.50 points

Pumps and continuous glucose monitors in Australia, Japan, Korea and urban China add 0.50 points by keeping type 1 patients on rapid-acting analogues. Glucose sensors are sized in our Continuous Glucose Monitoring Sensor Manufacturing Market report.

What holds back insulin revenue: bulk-buying, GLP-1 copies or Japan’s ageing patient base?

Three restraints hold back Asia Pacific insulin revenue: GLP-1 drugs remove 0.90 points of volume, bulk-buying and copies remove 1.60 points of net revenue per patient, and Japan’s ageing population holds its growth to 0.80% a year.

Glucagon-like peptide-1 (GLP-1) drugs delay insulin. Semaglutide lost patent protection in India on 21 March 2026, and within weeks nearly 40 Indian drug makers were selling copies at about Rs 2,000 to Rs 3,500 a month, The South First reported. Once a weekly GLP-1 injection costs about what basal insulin costs, some type 2 patients will take it first; Douglas Insights removes 0.90 points, leaving the 4.40% net volume leg.

On revenue per patient, procurement and copies remove 1.60 points a year: China’s first insulin round cut prices by an average 48% and the second by a further 3.8 points, Yicai reported. Novo Nordisk’s Region China and APAC insulin sales each fell 5% at constant exchange rates in the first quarter of 2026, according to its first-quarter 2026 report. The shift from human insulin to analogues and from vials to pens adds 1.10 points back, leaving -0.50%.

Japan is the third brake. It has the region’s highest prices but an ageing, shrinking population, so its insulin value grows only 0.80% a year in our model, and yearly drug price revisions trim older brands.

Where is insulin used most in Asia Pacific: China, Japan or India?

China uses the most insulin in Asia Pacific, USD 2.83 billion or 48.0% of 2025 value, nearly three times Japan’s USD 1.03 billion. India grows fastest, 7.60% a year to USD 1.04 billion by 2035, as diagnosis and access widen.

China, USD 2.83 billion, leads on the world’s largest diabetic population and hospital-based insulin starts, and grows 3.45% a year as volume rises faster than tendered prices fall; Novo Nordisk’s DKK 9,902 million of Region China insulin, USD 1.50 billion at DKK 6.60, is about half of it. Japan, USD 1.03 billion, has the highest price per patient in the region but grows only 0.80% because its population is shrinking.

India, USD 501 million, grows fastest at 7.60% a year because more of its adults with diabetes are being diagnosed and human insulin is giving way to analogue pens, although semaglutide copies cap the upside. Southeast Asia, USD 483 million, covering Indonesia, Thailand, Vietnam, the Philippines and Malaysia, grows 6.30% on universal health coverage schemes. South Korea, USD 295 million, grows 2.70%; Australia, USD 271 million, 2.90% on type 1 technology; the Rest of Asia Pacific, USD 483 million, including Taiwan, Pakistan, Bangladesh and New Zealand, 5.40%. Country values for 2035 sum to USD 8.58 billion, 0.45% below the headline; in the data table the row labelled Global holds the Asia Pacific total, USD 5.89 billion in 2025.

Who sells the insulin: Novo Nordisk, Gan & Lee, Sanofi, Lilly or Tonghua Dongbao?

Novo Nordisk sells the most insulin in Asia Pacific, about 44.3% of 2025 value, USD 2.61 billion, Douglas Insights estimates. Sanofi holds about 14.0%, Lilly 13.5% and Gan & Lee 8.5%, so four companies hold 80.3%.

The shares are Douglas Insights estimates, because no company reports Asia Pacific insulin sales on one basis. Novo Nordisk’s Region China and APAC insulin together reached DKK 15,247 million in 2025, USD 2.31 billion, with volume shares of 41.0% and 52.4%, its 2025 financial report states; adding India and Southeast Asia, which sit in its Emerging Markets region, gives our USD 2.61 billion. Gan & Lee’s CNY 4.05 billion of 2025 revenue, about USD 563 million at CNY 7.19, includes its overseas sales, so its Asia Pacific insulin estimate is USD 501 million.

The gap between Novo and Gan & Lee is narrowing: Gan & Lee’s revenue rose 33.1% in 2025 while Novo’s China insulin rose 5%. Sanofi’s Lantus and Toujeo and Lilly’s Humalog hold value in Japan, Korea and Australia, where procurement is less aggressive. The same companies’ positions in all medicines are compared in our Asia Pacific Pharmaceutical Drug Market report.

What does a year of insulin cost a patient in China, India and Japan?

An Asia Pacific insulin patient-year earned manufacturers an average net USD 298 in 2025, about USD 25 a month, Douglas Insights estimates: 43% below the USD 521 global average and 65% below the U.S. level.

Prices span a factor of about five. Human insulin vials in India and Bangladesh cost manufacturers under USD 100 a patient-year, while analogue pens in Japan earn more than USD 700, Douglas Insights estimates. In China, the procurement pen price sets the floor for everyone: Gan & Lee’s glargine rose 33% to CNY 65.30 in the second round while Lilly’s lispro premix doubled to CNY 38.42 from round-one lows, Yicai reported, a sign that the deepest cuts are over. The regional average falls to USD 296 in 2026 and USD 283 in 2035 because growth comes most from low-price India and Southeast Asia.

Which rules shape insulin: China’s bulk-buying contracts, weekly insulin approvals or India’s patent expiry?

Three rules shape the Asia Pacific insulin drug market: China’s national insulin procurement contracts, product approvals such as China’s March 2026 approval of Kyinsu, and India’s 21 March 2026 semaglutide patent expiry.

China’s insulin procurement, first effective in May 2022 and renewed in 2024, fixes pen prices for public hospitals in exchange for guaranteed volume; more than 35,000 institutions submitted demand in the second round, and 49 of 53 products bid were accepted, Yicai reported. The policy is why Gan & Lee and Tonghua Dongbao gained volume and why Douglas Insights holds China’s price leg below zero to 2035.

Product approvals decide how fast weekly insulin arrives. China approved Novo Nordisk’s Kyinsu, a once-weekly combination of insulin icodec and semaglutide, in March 2026, with launch planned for the second half of 2026, according to Novo Nordisk’s first-quarter 2026 report. Whether such products then win a place on China’s national reimbursement list, which the National Healthcare Security Administration (NHSA) updates every year, decides whether they reach public hospitals at scale.

India’s patent law is the third lever. Semaglutide’s patent expiry in March 2026 put cheap weekly GLP-1 copies next to insulin on pharmacy shelves, and India’s drug price regulator can also cap the price of insulins on its essential medicines list. In Japan, the government revises the national drug price list every year, which cuts the price of older insulin brands steadily.

What if GLP-1 copies win or bulk-buying spreads: where does insulin land in 2035?

The Asia Pacific insulin drug market ends 2035 between USD 6.88 billion and USD 10.6 billion across our three cases, around a base of USD 8.62 billion. Access in India and GLP-1 substitution set the spread.

In the slower case semaglutide copies in India and China delay insulin for millions of type 2 patients and procurement spreads to Southeast Asia, cutting prices again. In the faster case China’s county hospitals and India’s public programmes start insulin earlier and weekly basal products win reimbursement. One extra point of yearly volume growth adds USD 862 million to 2035 value; one point less removes USD 791 million.

Our 3.88% base matches the Asia Pacific row of our global insulin model, the fastest of five regions, against 1.95% for Europe and 2.46% worldwide, because Asia adds patients while Gan & Lee’s 33.1% revenue growth shows the volume is already arriving.

Douglas Exclusive: the Insulin and GLP-1 Annual Cost Ladder

The Insulin and GLP-1 Annual Cost Ladder is a Douglas Insights model built from 10 published prices and volumes in 6 company, procurement and press documents of 2024 to 2026, converting each into the cost of one patient-year.

The finding, a Douglas Insights estimate: in India a year of the cheapest semaglutide copy, about USD 279, now costs about the same as a year of China’s tendered glargine, about USD 276, and less than the regional insulin average of USD 298. That parity is new in 2026 and explains the 0.90-point GLP-1 deduction in our volume leg. It does not stop insulin growth, because people with type 1 diabetes and type 2 patients whose own insulin has failed still need it, but it moves the first injection for many type 2 patients from insulin to a GLP-1 drug, and it caps how far analogue pens can raise revenue per patient in India.

How does the methodology turn 19.8 million patient-years into USD 5.89 billion of insulin?

Our methodology multiplies 19.8 million insulin patient-years used in Asia Pacific in 2025 by an average net USD 298 per patient-year to reach USD 5.89 billion. Patients come from International Diabetes Federation counts; price from filings and procurement results.

The model covers 7 countries or sub-regions, 4 insulin classes, 2 diabetes types, 3 delivery formats and 2 channels, and uses 58 data points, 14 sourced and 44 modelled. Arithmetic: 19.8 million x USD 297.55 = USD 5,891 million, or USD 5.89 billion; 5.89 x (1.0440 x 0.9950)^10 = USD 8.62 billion. Patient-years reach 20.7 million in 2026 and 30.5 million in 2035.

Two cross-checks agree. First, Novo Nordisk’s USD 1.50 billion of Region China insulin at a 41.0% volume share implies a China market of up to USD 3.66 billion if its prices matched rivals’; because Novo sells more premium analogues than tender-priced local copies, its value share is higher, and our China figure of USD 2.83 billion sits below that ceiling. Second, USD 5.89 billion equals the Asia Pacific row of our worldwide insulin model and our 3.88% matches it. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. Novo Nordisk / SEC Financial report for 2025 (Form 6-K) (2026)
2. Novo Nordisk / SEC Financial report for the first three months of 2026 (Form 6-K) (2026)
3. International Diabetes Federation Diabetes Atlas: Western Pacific region data (2025)
4. International Diabetes Federation Diabetes Atlas: South-East Asia region data (2025)
5. Yicai Global Round two of China's insulin bulk-buy scheme drives prices down further (2024)
6. Tencent News Gan & Lee 2025 annual results (2026)
7. The South First Generic competition slashes semaglutide prices after patent expiry (2026)

What does this insulin study cover, and what falls outside it?

The Asia Pacific insulin drug market counts manufacturer net sales of human and analogue insulins, weekly basal insulins and basal combinations used across Asia Pacific. Glucagon, GLP-1 drugs alone, pumps, pen needles and pharmacy margins stay out.

The by-class split covers long-acting insulin analogues, rapid-acting insulin analogues, premix insulins and human insulin. The by-diabetes-type split covers type 1 diabetes and type 2 diabetes. The by-format split covers prefilled pens, cartridges and vials. The by-channel split covers hospital pharmacies and retail pharmacies. The by-country split covers China, Japan, India, Southeast Asia, South Korea, Australia and the Rest of Asia Pacific. Values are net of procurement discounts and rebates and are counted where the insulin is used, so Chinese insulin exported to Europe or Latin America is excluded.